Apatinib as an alternative therapy for advanced hepatocellular carcinoma.
World J Hepatol
; 12(10): 766-774, 2020 Oct 27.
Article
en En
| MEDLINE
| ID: mdl-33200015
ABSTRACT
Angiogenesis plays an important role in the occurrence and development of tumors. Registered tyrosine kinase inhibitors targeting vascular endothelial growth factor reduce angiogenesis. Apatinib, a tyrosine kinase inhibitor, can specifically inhibit vascular endothelial growth factor receptor 2, showing encouraging anti-tumor effects in a variety of tumors including advanced hepatocellular carcinoma (HCC). This article intends to review the clinical research and application prospects of apatinib in the field of HCC.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
World J Hepatol
Año:
2020
Tipo del documento:
Article
País de afiliación:
China